BNET Industries
Sepracor Inc. (SEPR) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $1.2B
- Profit
- Dec 31 2007
- $58.3M
- Market Cap
- Nov 28 2008
- $1.2B
Latest News and Analysis
Morning Stock News You Can Use.
M2 PRESSWIRE-2 January 2008-StockProfiler.US: Morning Stock News You Can UseC1994-2008 M2 COMMUNICATIONS LTD RDATE:02012008 New York, NY -- StockProfilers' "Stock News" For This Morning: ArthroCare Corp. (NASDAQ: ARTC); Celera (NYSE:CRA); LHC Group, Inc. (NASDAQ: LHCG);...
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2007 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its third quarter 2007 financial results on Oct. 30, 2007. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on Oct. 30, 2007 to discuss its third quarter 2007 financial...
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2007 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2007 financial results on July 27, 2007. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on July 27, 2007 to discuss its second quarter 2007 financial...
Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2006 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its fourth quarter and full-year 2006 financial results on January 31, 2007. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on January 31, 2007 to discuss its fourth quarter...
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2006 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its third quarter 2006 financial results on Oct. 26, 2006. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on Oct. 26, 2006 to discuss its third quarter 2006 financial...
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2006 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2006 financial results on July 21, 2006. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on July 21, 2006 to discuss its second quarter 2006 financial...
Sepracor Inc. Sets Conference Call and Webcast for First Quarter 2006 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its first quarter 2006 financial results on April 25, 2006. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on April 25, 2006 to discuss its first quarter 2006 financial...
Sepracor Inc. Sets Conference Call and Webcast for Fourth Quarter and Full-Year 2005 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its fourth quarter and full-year 2005 financial results on January 31, 2006. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on January 31, 2006 to discuss its fourth quarter...
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter 2005 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its third quarter 2005 financial results on October 25, 2005. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on October 25, 2005 to discuss its third quarter 2005 financial...
Sepracor Inc. Sets Conference Call and Webcast for Second Quarter 2005 Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its second quarter 2005 financial results on July 19, 2005. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on July 19, 2005 to discuss its second quarter 2005 financial...
Additional Resources
Acorda Therapeutics Names Thomas C. Wessel, M.D., Ph.D., as Chief Medical Officer
HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Thomas C. Wessel, M.D., Ph.D., has joined the Company as Chief Medical Officer, reporting to Ron Cohen, M.D., President and CEO. In this role, Dr. Wessel will have responsibility for the Company's Clinical Development and Operations, Regulatory Affairs, Biostatistics,...
Results of Studies of ALVESCO® for the Treatment of Asthma and OMNARIS™ in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
* Phase III results show improvements in asthma symptom control for marketed doses of ALVESCO HFA hydrofluoroalkane * ALVESCO HFA treatment shown to be safe and well-tolerated * Ciclesonide in an HFA MDI (metered-dose inhaler) nasal aerosol, in development for treatment of allergic rhinitis, was well-tolerated...
Zacks Analyst Blog Highlights: Smith International, Inc., WellPoint, Inc., Ltd., Rent-A-Center, Inc., Sepracor Inc. and News Corporation, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Smith International, Inc. (NYSE: SII), WellPoint, Inc. (NYSE: WLP), Rent-A-Center, Inc....
Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance
Financial Highlights * Third quarter 2008 revenues increased 9.6% to $307.7 million compared to third quarter 2007 * Reported earnings per share EPS for third quarter 2008 were $0.17 per diluted share vs. $0.34 per diluted share for same period in 2007 * Excluding...
Britts leaves Sepracor to become Merz president, CEO
Jack Britts has been appointed president and chief executive officer of Merz Pharmaceuticals LLC. A pharmaceutical industry veteran who joins Merz from Sepracor Inc., Britts will oversee the growth of the company's medical dermatology business and establish units to support Merz's aesthetics and neurology pipeline...
European Medicines Agency Issues Positive Opinion For LUNIVIA® Marketing Authorization Application In Europe
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use CHMP has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA([R]) brand eszopiclone in the European Union EU for the treatment of insomnia. The EU labeling provides for...
Sepracor Inc. Sets Conference Call and Webcast for Third Quarter Operating Results
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) will announce its third quarter 2008 financial results on October 28, 2008. In conjunction with the press release, Sepracor will host a conference call and live webcast beginning at 8:30 a.m. ET on October 28, 2008 to discuss its third quarter 2008 financial...
Zacks Sell List Highlights: Sepracor, CRA International, Owens-Illinois and Ciena Corp
CHICAGO -- Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List - Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 Strong Sell: Sepracor, Inc. (NASDAQ: SEPR) and CRA International, Inc. (NASDAQ: CRAI). Further, Zacks...
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
* Presentation included results of three Phase III studies of eslicarbazepine acetate in more than 1,000 patients with refractory partial epilepsy * Studies demonstrated marked and sustained seizure reduction and significant improvement in quality of life and depressive symptoms over a one-year treatment period * U.S....
Pulmatrix Appoints John P. Hanrahan Chief Medical Officer
LEXINGTON, Mass. -- Pulmatrix Inc., a biotechnology company commercializing a broad new class of treatments for respiratory disease, announced today the appointment of John P. Hanrahan, M.D., M.P.H., as Senior Vice President and Chief Medical Officer. Dr. Hanrahan will lead the Company's clinical development programs beginning with Phase II trials...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 1984
- CEO: Mr. Adrian Adams
Sepracor is pharmaceutical company that develops and commercializes products prescribed by physicians and specialists. At Dec 31 2007, Co.'s marketed products included: XOPENEX® Inhalation Solution for the treatment or prevention of bronchospasm in patients six years of age and older with reversible obstructive airway disease; XOPENEX HFA® Inhalation Aerosol for the treatment or prevention of bronchospasm in adults, adolescents and children of four years of age and older with reversible obstructive airway disease; BROVANA® Inhalation Solution for the treatment of bronchoconstriction patients with chronic obstructive pulmonary disease; and LUNESTA® for the treatment of insomnia in adults.
Key Competitors
Industry Transcripts by Seeking Alpha
-
Indevus Pharmaceuticals, Inc. F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 25, 2008about IDEV
-
Noven Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about NOVN
-
XenoPort, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about XNPT
-
Repligen Corporation F2Q09 (Qtr End 09/30/08) Earnings Call Transcript
on Nov 24, 2008about RGEN
-
Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript
on Nov 24, 2008about OMRI
Sepracor Inc. Company Info
Board of Directors
Mr. Timothy J. Barberich
Chairman
Mr. William J. O'Shea
Vice-Chairman
Mr. Robert J. Cresci
Lead Director
Mr. Digby W. Barrios
Mr. Alan A. Steigrod
Mr. Timothy J. Rink
Mr. James F. Mrazek
Ms. Lisa Ricciardi
Contact Information
84 Waterford Drive
Marlborough, MA
508 481-6700